Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis

Clin Infect Dis. 2020 Feb 14;70(5):943-946. doi: 10.1093/cid/ciz577.

Abstract

We evaluated an elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen could be appropriate for postexposure prophylaxis.

Clinical trials registration: NCT02998320.

Keywords: HIV; adherence; adverse events; completion; postexposure prophylaxis.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Alanine
  • Anti-HIV Agents* / therapeutic use
  • Cobicistat / therapeutic use
  • Drug Combinations
  • Emtricitabine / therapeutic use
  • HIV Infections* / drug therapy
  • HIV Infections* / prevention & control
  • HIV-1*
  • Humans
  • Quinolones
  • Tablets / therapeutic use
  • Tenofovir / analogs & derivatives

Substances

  • Anti-HIV Agents
  • Drug Combinations
  • Quinolones
  • Tablets
  • elvitegravir
  • Tenofovir
  • tenofovir alafenamide
  • Emtricitabine
  • Adenine
  • Cobicistat
  • Alanine

Associated data

  • ClinicalTrials.gov/NCT02998320